In the name of god Target IOP S.M.Shahshahan M.D Feb 2010.

Slides:



Advertisements
Similar presentations
Everything you need to know. Glaucoma is an eye condition in which the optic nerve at the back of the eye is damaged. The optic nerve is responsible for.
Advertisements

V Glaucoma Implementing NICE guidance 2009 NICE clinical guideline 85.
Laser treatment in glaucoma
Placido Based Corneal Topography
The target IOP is the mean IOP obtained with treatment that prevents further glaucomatous damage in the eye of the individual under consideration. The.
OCT (Optic Coherence Tomography) 1)Noninvasive 2) non-contact imaging 3)Millimeter penetration Aproximately 2-3 mm in tissue with micrometer scale (axial.
OHT Treatment criteria First Choice Treatment Dr. Jordi Loscos Arenas Hospital Universitari Germans Trias i Pujol, Barcelona.
What is wave front.
The most common complication of cataract surgery by means of ECCE or phacoemulsification is opacification of the intact posterior capsule.
TOPOGRAPHY ORBSCAN S.A.A. Mortazavi MD.
Biomechanical Properties of the Cornea in Normal- Tension Glaucoma Authors: Leonidas Traipe Ines Cayuqueo Fabiola Cerfogli Claudia Goya Allister Gibbons.
PHAKIC IOL’S ( pIOL’S ) IN CORRECTING HIGH MYOPIA By: H.R. ZIAI MD. Esfand 1391 Isfahan.
1 In the name of god In the name of god 2 Viscoelastics It is better to term them Ophthalmic Viscosurgical Device OVDS Dr.sayyed ezatollah memarzadeh.
Perimetry visual field Akram Rismanchian MD Farabi Hospital.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
IN THE NAME MY GOD 1. Phacoemulsification in long and short eyes Dr. memarzadeh MD 1387/11/ Dr memarzadeh MD ophthalmologist 2.
© INTERNATIONAL GLAUCOMA ASSOCIATION (274681) 2009 The International GLAUCOMA Association Subhash Suthar D Pharm Development Manager.
Clinical Guidance and Monitoring for Change Cecilia Fenerty MD FRCOphth.
IN THE NAME OF GOD TREATMENT OF PEDIATRIC GLAUCOMA S.M SHAHSHAHAN M.D FEB 2013.
Medical Therapy in Glaucoma M. GHASSAMI MD Medical Therapy in Glaucoma The Ocular Hypertension Treatment Study demonstrated that topical ocular hypotensive.
Presented by A. Rismanchian MD Farabi Hospital Clinical Aspects Of OPTICAL COHERENCE TOMOGRAPHY IN GLAUCOMA.
Endothelium Protection In Phacoemulsification H.R. Ziai MD.
Fluorescein Angiography & OCT in Diabetic Retinopathy
Nonsurgical management of diabetic retinopathy Ghanbari MD 1388:11:30.
1- Ant Chamber 2- Iris Plane 3- Post chamber 4- Supracapsular 5) Endolenticular.
Astigmatism correction methods
ENDOPHTHALMITIS DR ALI SALEHI Endophthalmitis Is a serious condition that can result in permanent and dramatic loss of vision. Early diagnosis and treatment.
Approach to pediatric retinal disease
0 Glaucoma can take your sight away. Keep Vision in Your Future.
I.A and IOL Implantation A.R.Ashtari MD 1387 ADVANTAGES OF COMPLETE CORTICAL ASPIRATION a.Faster recovery of visual acuity b.Decrease postoperative uveitis.
Assessment and Management of Patients With Eye and Vision Disorders
IOLs & Biometry Alireza Peyman, MD Isfahan University of Medical Sciences.
Surgical treatment for Diabetic Retinopathy.
In the name of God Glaucoma Drainage Devices S.M.Shahshahan M.D Feb 2010.
The Canadian Association of Optometrists
Dr. Amin Hossein Rahgozar
OPEN ANGLE GLAUCOMA Frank J. Weinstock, MD, FACS Professor of Ophthalmology- NEOUCOM Canton, Ohio USA.
Chemical injuries 1. Mild irritation 2. Complete destruction of the ocular surface epithelium and corneal opacification, loss of vision and rarely loss.
Isfahan University of Medical sciences
ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute of Ophthalmology ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute.
 GLAUCOMA.  BY GROUPS 3 1. Siti Hadijah ( ) 2. I Putu Adi Styawan ( ) 3. Jaka Primadhana. R ( ) 4. Komang Ayu Pradnya Antari ( )
Will my Glaucoma patient lose vision ?
RANDOMIZED CLINICAL TRIALS IN GLAUCOMA- WHAT DO THEY TELL US? Dr Jyoti Shetty B.W.Lions superspeciality eye hospital.
TARIQ ALASBALI WHICH PATIENTS ARE AT RISK FOR THE PROGRESSION?
Retinal nerve fiber layer thickness change in patients with wet AMD treated with ranibizumab, short term results Advantages: To determine the effect of.
Target pressures are not achieved Neural tissue of visual function is progressively lost despite maximally tolerated medical and laser therapies.
Effect of Corneal Thickness on Selective Laser Trabeculoplasty to Decrease Intraocular Pressure as Primary or Secondary Treatment of Glaucoma ASCRS 2010.
Small pupil phacoemulcifiction A preoperative evaluation should include pupillary dynamics Poor pupillary dilatation should be detected and noted Appropriate.
E-Poster Rio de Janeiro Corneal Tomography and Biomechanics Study Group The study of the correlations of the optic disc size with Cornal Geometry and Biomechanical.
Glaucoma Care Project Team Members: Geoffrey T. Emerick, M.D. Erin Herlihy, B.S. Marilyn Hauser, M.B.A. Dianna Greening, R.N. Walter M. Jay, M.D Opportunity.
Glaucoma.
Glaucoma Madhav Vempali Vempali Medical Ltd. Glaucoma The healthy eye Light rays enter the eye through the cornea, pupil and lens. These light rays are.
Mr. A. Waldock MD BMed Sci (Hons) BM BS FRCOphth Consultant Ophthalmic Surgeon Ophthalmology Training Programme Director, East of England Deanery.
Glaucoma Lily T. Im, MD. What is glaucoma?   Glaucoma is a group of diseases that damage the eye’s optic nerve and can result in vision loss and blindness.
Ophthalmology – Raised IOP Referrals (Adults only)
Target IOP Update Mohamed Yasser Sayed Saif Beni Suef University
Review of Glaucoma Suspect
Neuroretinal Rim Recovery In Narrow Angle Glaucoma After Intraocular Pressure Lowering With Topical Medications  – Case Report Božić M.1,2, Marković V.
Pathogenesis of Glaucoma Translaminar-pressure difference
Clinical effect of citicoline combined with choline alfoscerate for treatment of glaucomatous optic neuropathy Karliychuk M.A., Pinchuk S.V. Department.
Glaucoma.
بسم الله الرحمن الرحیم.
Ant Uveitis Uveitis Posterior Uveitis Pan Uveitis Iritis iridocyclitis.
 In modern phaco surgeons no longer seek to avoid inducing ast
بسم الله الرحمن الرحیم.
IN THE NAME OF GOD.
Clinical Cases in Glaucoma Treatment
Presentation transcript:

In the name of god

Target IOP S.M.Shahshahan M.D Feb 2010

History In the early 1960 Chandler has observed the need for varying target IOPs according to the severity of glaucoma.

Definition (AAO) Target IOP The upper limit of the range of measured IOP adequate to stop progressive pressure induced injury of the optic nerve.

Definition (The european glaucoma society) Estimate of the mean IOP obtained with treatment that is expected to prevent further glaucomatous damage.

IOP Is the only known risk factor which can be modified to arrest or slow progressive glaucomatous optic neuropathy.

Most important factors for target IOP level 1-Severity of glaucomatous damage to optic nerve head 2-Age 3-Baseline IOP 4-Central corneal thickness 5-Associated ocular disease 6-Risk of treatment 7-Systemic morbidity

1-Severity of glaucomatous damage to optic nerve head The optic nerve head evaluation(C/D ratio) Extent of visual field loss -Visual field loss encroaching on fixation

2-Age There is gradual,steady decrease in the number of the nerve fibers ( 4% - 5% per decade after the age of 50 ). Elderly patients with early glaucoma may not need to be treated aggressively unless central fixation is threated. (Lower target IOPs in young patients) Life expectancy

3-Baseline IOP It is essential to get an accurate estimate of the baseline IOP(Mean of 4-6 IOP at different times). The risk of progression increases significantly with increasing IOP.

4-Central corneal thickness In the OHTS : the risk for developing glaucoma doubles for every 40 microns of CCT thining. CCT is an indipendent predictor of glaucoma. The effect of CCT on IOP measurement is probably not important except in the eyes with extremely thick or thin corneas.

5-Associated ocular diseases: Pseudoexfoliation has been associated with an increased risk of conversion from OHT to POG.

6-Risk of treatment There is a significant association between cardiovascular mortality and glaucoma particularly in patients also treated with topical Timolol ( The blue mountain eye study) In older individual or early glaucoma,it may be acceptable to leave the IOP higher than the target,rather than prescribe topical B-blockers or prefer glaucoma surgery.

7-Systemic morbidity Studies are ongoing looking into non-IOP factors (such as hypertension and D.M) contributing to the disease.

ضمن عرض پوزش بدلیل حجم بالای LECTUER ادامه اسلایدها امکان پذیر نمیباشد در صورت نیاز به ادامه لطفا به واحد سمعی و بصری مرکز آموزشی درمانی فیض مراجعه و یا با شماره تلفن داخلی 392 تماس حاصل نمائید با تشکر